Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrophage acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Manni, Simona, Del Bufalo, Francesca, Merli, Pietro, Silvestris, Domenico Alessandro, Guercio, Marika, Caruso, Simona, Reddel, Sofia, Iaffaldano, Laura, Pezzella, Michele, Di Cecca, Stefano, Sinibaldi, Matilde, Ottaviani, Alessio, Quadraccia, Maria Cecilia, Aurigemma, Mariasole, Sarcinelli, Andrea, Ciccone, Roselia, Abbaszadeh, Zeinab, Ceccarelli, Manuela, De Vito, Rita, Lodi, Maria Chiara, Cefalo, Maria Giuseppina, Mastronuzzi, Angela, De Angelis, Biagio, Locatelli, Franco, Quintarelli, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256701/
https://www.ncbi.nlm.nih.gov/pubmed/37296093
http://dx.doi.org/10.1038/s41467-023-38723-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256701/
https://www.ncbi.nlm.nih.gov/pubmed/37296093
http://dx.doi.org/10.1038/s41467-023-38723-y

Ejemplares similares